-

Ignyte Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

NEW YORK--(BUSINESS WIRE)--Ignyte Acquisition Corp. (NASDAQ:IGNYU) (the “Company”) today announced that on May 28, 2021 it received a notice from Nasdaq Regulation indicating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission (the “SEC”).

The Nasdaq notice has no immediate effect on the listing or trading of the Company’s units, Class A ordinary shares or warrants on the Nasdaq Capital Market. The Notice provides that the Company must submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) by July 26, 2021. If the plan is accepted by Nasdaq, then Nasdaq can grant the Company up to 180 calendar days from the due date of the Form 10-Q, or November 22, 2021, to regain compliance.

As the Company reported in its Form 12b-25 filed with the SEC on May 17, 2021, the Company is working diligently to complete the Form 10-Q as soon as possible; however, given the scope of the process for evaluating the impact on the Company’s financial statements of the Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”) issued by the staff of the SEC on April 12, 2021, the Company is not in a position to file the Form 10-Q until after the completion of this process.

This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and prospectus for its initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law.

Contacts

David Rosenberg
Co-Chief Executive Officer
Ignyte Acquisition Corp.
drosenberg@ignytespac.com

Ignyte Acquisition Corp.

NASDAQ:IGNY

Release Versions

Contacts

David Rosenberg
Co-Chief Executive Officer
Ignyte Acquisition Corp.
drosenberg@ignytespac.com

More News From Ignyte Acquisition Corp.

Peak Bio, Inc. Announces Closing of up to $100 Million Common Stock Purchase Transaction with White Lion Capital

PALO ALTO, Calif.--(BUSINESS WIRE)--Peak Bio, Inc. ("Peak Bio" or the "Company") (NASDAQ: PKBO), a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory diseases, today announced that it has entered into a Common Stock Purchase Agreement (the "Agreement") with White Lion Capital, LLC ("White Lion Capital"). The Agreement governs a committed equity facility that provides the Company with the right, without the obliga...

Peak Bio Co., Ltd. to List on NASDAQ Following Successful Business Combination with Ignyte Acquisition Corp.

NEW YORK--(BUSINESS WIRE)--Peak Bio Co., Ltd. (“Peak Bio”), a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory diseases, today announced the completion of its business combination (the “Business Combination”) with Ignyte Acquisition Corp. (Nasdaq: IGNY) (“Ignyte”), a special purpose acquisition company. The transaction was approved at a special meeting of Ignyte’s stockholders held on October 25, 2022 (the “Spe...

Ignyte Acquisition Corp. Stockholders Approve Proposed Business Combination with Peak Bio

NEW YORK--(BUSINESS WIRE)--Ignyte Acquisition Corp. (“Ignyte”) (NASDAQ: IGNY), a publicly traded special purpose acquisition company, today announced that Ignyte’s stockholders have approved its proposed business combination (the “Business Combination”) with Peak Bio Co., Ltd. (“Peak Bio”) at a Special Meeting of its stockholders held on October 25, 2022 (the “Special Meeting”). The Special Meeting to be held on October 31, 2022 has been canceled. Approximately 75% of the votes cast at the Spec...
Back to Newsroom